Linked Life Data

21941554

Source:http://linkedlifedata.com/resource/pubmed/id/21941554

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2011-9-23
pubmed:abstractText
An elevated serum level of NM23-H1 protein is a poor prognostic factor in patients with various hematologic malignancies. The extracellular NM23-H1 protein promotes the in vitro growth and survival of acute myelogenous leukemia (AML) cells and inversely inhibits the in vitro survival of normal peripheral blood monocytes in primary culture at concentrations equivalent to the levels found in the serum of AML patients. The growth and survival promoting activity to AML cells is associated with cytokine production and activation of mitogen-activated protein kinases (MAPKs) and signal transducers and activators of transcription (STAT) signaling pathways. Inhibitors specific for MAPK signaling pathways inhibit the growth/survival-promoting activity of NM23-H1. These findings indicate a novel biological action of extracellular NM23-H1 and its association with poor prognosis. These results suggest an important role of extracellular NM23-H1 in the malignant progression of leukemia and a potential therapeutic target for these malignancies.
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:issn
1687-9112
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
2012
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
879368
pubmed:year
2012
pubmed:articleTitle
Extracellular NM23 Protein as a Therapeutic Target for Hematologic Malignancies.
pubmed:affiliation
Research Institute for Clinical Oncology, Saitama Cancer Center, Komuro 818, Ina-machi, Saitama 362-0806, Japan.
pubmed:publicationType
Journal Article